Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin

References

• AnandSXKimMCKamranMComparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudinAm J Cardiol20071004172417659921
   PubMedGoogle Scholar
• AndersonJLAdamsCDAntmanEMACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction developed in collaboration with the American College of Emergency Physicians the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineJ Am Coll Cardiol200750e1e15717692738
   PubMed Web of Science ®Google Scholar
• APPROVEThe Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day resultsJ Invasive Cardiol200416651615550739
   PubMedGoogle Scholar
• AroraUKDhirMDirect thrombin inhibitors part 1 of 2J Invasive Cardiol20051734815640538
   PubMedGoogle Scholar
• BatesERBivalirudin: an anticoagulant option for percutaneous coronary interventionExpert Rev Cardiovasc Ther200421536215151464
   PubMedGoogle Scholar
• BatesSMWeitzJIDirect thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudinAm J Cardiol19988212P18P
   PubMed Web of Science ®Google Scholar
• BeckerDLFredenburghJCStaffordARExosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor IIJ Biol Chem199927462263310037709
   PubMed Web of Science ®Google Scholar
• BittlJAComparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study InvestigatorsAm Heart J1995130658657668214
   PubMed Web of Science ®Google Scholar
• BittlJAChaitmanBRFeitFBivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty StudyAm Heart J2001142952911717596
   PubMed Web of Science ®Google Scholar
• BittlJAStronyJBrinkerJATreatment with bivalirudin Hirulog. as compared with heparin during coronary angioplasty for unstable or postinfarction angina Hirulog Angioplasty Study InvestigatorsN Engl J Med199533376497643883
   PubMed Web of Science ®Google Scholar
• BrenerSJMoliternoDJLincoffAMRelationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary interventionCirculation2004110994815302778
   PubMed Web of Science ®Google Scholar
• BurkeAPFarbAMalcomGTEffect of risk factors on the mechanism of acute thrombosis and sudden coronary death in womenCirculation199897211069626170
   PubMed Web of Science ®Google Scholar
• BurkeAPFarbAMalcomGTCoronary risk factors and plaque morphology in men with coronary disease who died suddenlyN Engl J Med19973361276829113930
   PubMed Web of Science ®Google Scholar
• CairnsJAGentMSingerJAspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trialN Engl J Med19853131369753903504
   PubMed Web of Science ®Google Scholar
• CannonCPMaraganoreJMLoscalzoJAnticoagulant effects of hirulog a novel thrombin inhibitor in patients with coronary artery diseaseAm J Cardiol199371778828456753
   PubMed Web of Science ®Google Scholar
• CAPRIEA randomized blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events CAPRIE. CAPRIE Steering CommitteeLancet19963481329398918275
   PubMed Web of Science ®Google Scholar
• ChamberlinJRLewisBLeyaFSuccessful treatment of heparin-associated thrombocytopenia and thrombosis using HirulogCan J Cardiol19951151147780873
   PubMed Web of Science ®Google Scholar
• ChongBHHeparin-induced thrombocytopeniaJ Thromb Haemost200311471812871282
   PubMed Web of Science ®Google Scholar
• CohenMAdamsPCParryGCombination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research GroupCirculation1994898188281698
   PubMed Web of Science ®Google Scholar
• DaLHeparin binding and neutralizing proteins1989Boca RatonCRC Press
   Google Scholar
• De RomeufCMazurierCHeparin binding assay of von Willebrand factor vWF in plasma milieu – evidence of the importance of the multimerization degree of vWFThromb Haemost199369436408322266
   PubMed Web of Science ®Google Scholar
• Di NisioMMiddeldorpSBullerHRDirect thrombin inhibitorsN Engl J Med200535310284016148288
   PubMed Web of Science ®Google Scholar
• DykeCMSmediraNGKosterAA comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON studyJ Thorac Cardiovasc Surg2006131533916515902
   PubMed Web of Science ®Google Scholar
• EikelboomJWMehtaSRAnandSSAdverse impact of bleeding on prognosis in patients with acute coronary syndromesCirculation20061147748216908769
   PubMed Web of Science ®Google Scholar
• EitzmanDTChiLSagginLHeparin neutralization by platelet-rich thrombi. Role of platelet factor 4Circulation199489152398149517
   PubMed Web of Science ®Google Scholar
• EresAUse of bivalirudin as the foundation anticoagulant during percutaneous peripheral interventionsJ Invasive Cardiol200618125816598112
   PubMedGoogle Scholar
• FentonJW2ndOfosuFABrezniakDVThrombin and antithromboticsSemin Thromb Hemost1998248791
   Web of Science ®Google Scholar
• FergusonJJCaliffRMAntmanEMEnoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trialJAMA2004292455415238590
   PubMed Web of Science ®Google Scholar
• FoxIDawsonALoyndsPAnticoagulant activity of Hirulog a direct thrombin inhibitor in humansThromb Haemost199369157638456428
   PubMed Web of Science ®Google Scholar
• FRISCLow-molecular-weight heparin during instability in coronary artery disease Fragmin during Instability in Coronary Artery Disease FRISC study groupLancet199634756188596317
   PubMedGoogle Scholar
• FurieBFurieBCMolecular and cellular biology of blood coagulationN Engl J Med199232680061538724
   PubMed Web of Science ®Google Scholar
• GibsonCMMorrowDAMurphySAA randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trialJ Am Coll Cardiol20064723647316781360
   PubMed Web of Science ®Google Scholar
• GibsonCMTenYMurphySAAssociation of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention A REPLACE-2 analysisAm J Cardiol20079916879017560876
   PubMed Web of Science ®Google Scholar
• GurfinkelEPManosEJMejailRILow molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemiaJ Am Coll Cardiol19952631387608429
   PubMed Web of Science ®Google Scholar
• GurmHSRajagopalVBhattDLThe safety of a bivalirudin-based approach in patients undergoing rotational atherectomyJ Invasive Cardiol200719225817476038
   PubMedGoogle Scholar
• HirshJHeparinN Engl J Med19913241565742027360
   PubMed Web of Science ®Google Scholar
• HoggPJBockPEModulation of thrombin and heparin activities by fibrinThromb Haemost199777424339065987
   PubMed Web of Science ®Google Scholar
• ISIS-2Randomised trial of intravenous streptokinase oral aspirin both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative GroupLancet19882349602899772
   PubMed Web of Science ®Google Scholar
• JabrKJohnsonJMcDonaldMHPlasma-modified ACT can be used to monitor bivalirudin Angiomax anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopeniaJournal of Extra-Corporeal Technology200436174715334761
   PubMedGoogle Scholar
• KingSB3rdSmithSCJrHirshfeldJWJr2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention A Report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation2007
   Google Scholar
• KumarRBeguinSHemkerHCThe influence of fibrinogen and fibrin on thrombin generation – evidence for feedback activation of the clotting system by clot bound thrombinThromb Haemost199472713217900079
   PubMed Web of Science ®Google Scholar
• KumarRBeguinSHemkerHCThe effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activityThromb Haemost19957496288571330
   PubMed Web of Science ®Google Scholar
• LeePCKiniASAhsanCAnemia is an independent predictor of mortality after percutaneous coronary interventionJ Am Coll Cardiol200444541615358017
   PubMed Web of Science ®Google Scholar
• LehmanSJChewDPBivalirudin in percutaneous coronary interventionVasc Health Risk Manag200623576317323589
   PubMedGoogle Scholar
• LewisHDJrDavisJWArchibaldDGProtective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative StudyN Engl J Med19833093964036135989
   PubMed Web of Science ®Google Scholar
• LidonRMTherouxPJuneauMInitial experience with a direct antithrombin Hirulog, in unstable angina Anticoagulant, antithrombotic, and clinical effectsCirculation19938814955018403297
   PubMed Web of Science ®Google Scholar
• LincoffAMBittlJAHarringtonRABivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialJAMA200328985363
   Web of Science ®Google Scholar
• LincoffAMBittlJAKleimanNSComparison of bivalirudin versus heparin during percutaneous coronary intervention the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trialAm J Cardiol2004931092615110198
   PubMed Web of Science ®Google Scholar
• LincoffAMKleimanNSKottke-MarchantKBivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial CACHETAm Heart J20021438475312040347
   PubMed Web of Science ®Google Scholar
• MahaffeyKWLewisBEWildermannNMThe anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia ATBAT study: main resultsJ Invasive Cardiol200315611614608128
   PubMedGoogle Scholar
• ManoukianSVFeitFMehranRImpact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY TrialJ Am Coll Cardiol2007491362817394970
   PubMed Web of Science ®Google Scholar
• MaraganoreJMBourdonPJablonskiJDesign and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombinBiochemistry19902970951012223763
   PubMed Web of Science ®Google Scholar
• McKechnieRSSmithDMontoyeCPrognostic implication of anemia on in-hospital outcomes after percutaneous coronary interventionCirculation2004110271715226214
   PubMedGoogle Scholar
• MehtaSRYusufSPetersRJEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet20013585273311520521
   PubMed Web of Science ®Google Scholar
• MerryAFBivalirudin, blood loss and graft patency in coronary artery bypass surgerySemin Thromb Hemost2004303374615282656
   PubMed Web of Science ®Google Scholar
• MerryAFRaudkiviPJMiddletonNGBivalirudin versus heparin and protamine in off-pump coronary artery bypass surgeryAnn Thorac Surg20047792531 discussion 93114992900
   PubMed Web of Science ®Google Scholar
• MirshahiMSoriaJSoriaCEvaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysisBlood1989741025302502207
   PubMed Web of Science ®Google Scholar
• OlerAWhooleyMAOlerJAdding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysisJAMA199627681158769591
   PubMed Web of Science ®Google Scholar
• ParryMAMaraganoreJMStoneSRKinetic mechanism for the interaction of Hirulog with thrombinBiochemistry19943314807147993908
   PubMed Web of Science ®Google Scholar
• RaoSVO’GradyKPieperKSImpact of bleeding severity on clinical outcomes among patients with acute coronary syndromesAm J Cardiol2005961200616253582
   PubMed Web of Science ®Google Scholar
• ReedMDBellDClinical pharmacology of bivalirudinPharmacotherapy200222105S111S12064567
   PubMed Web of Science ®Google Scholar
• RISCRisk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease The RISC GroupLancet1990336827301976875
   PubMed Web of Science ®Google Scholar
• RobsonRThe use of bivalirudin in patients with renal impairmentJ Invasive Cardiol200012Suppl F33F6
   PubMedGoogle Scholar
• RosamondWFlegalKFridayGHeart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation2007115e6917117194875
   PubMed Web of Science ®Google Scholar
• SakharovDVPlowEFRijkenDCOn the mechanism of the antifibrinolytic activity of plasma carboxypeptidase BJ Biol Chem199727214477829162090
   PubMed Web of Science ®Google Scholar
• SchaarJAMullerJEFalkETerminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque June 17 and 18, 2003, Santorini, GreeceEur Heart J20042510778215191780
   PubMed Web of Science ®Google Scholar
• SchrorKThe basic pharmacology of ticlopidine and clopidogrelPlatelets1993425261
   PubMed Web of Science ®Google Scholar
• SciulliTMMauroVFPharmacology and clinical use of bivalirudinAnn Pharmacother20023610284112022907
   PubMed Web of Science ®Google Scholar
• SharmaGVLapsleyDVitaJAUsefulness and tolerability of hirulog a direct thrombin-inhibitor, in unstable angina pectorisAm J Cardiol1993721357608256726
   PubMed Web of Science ®Google Scholar
• ShenGXXMFentonJWEffect of hirulog-1 on fibrinolysis and platelet deposition abstractAtherosclerosis1997134195
   Web of Science ®Google Scholar
• SmediraNGDykeCMKosterAAnticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF studyJ Thorac Cardiovasc Surg20061316869216515924
   PubMed Web of Science ®Google Scholar
• StellaJStellaDIaffaldanoRThe bivalirudin in the management of patients with ST-segment elevation acute myocardial infarction undergoing primary PCI BIAMI Trial. Society of Cardiovascular Angiography and Interventions2006
   Google Scholar
• StellaJFStellaREIaffaldanoRAAnticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarctionJ Invasive Cardiol200416451415353822
   PubMedGoogle Scholar
• StoneGWHORIZONS AMI: Bivalirudin reduces bleeding, adverse clinical events in STEMI2007Washington, D.CTCT
   Google Scholar
• StoneGWMcLaurinBTCoxDABivalirudin for patients with acute coronary syndromesN Engl J Med200635522031617124018
   PubMed Web of Science ®Google Scholar
• StoneGWWareJHBertrandMEAntithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trialJAMA2007a298249750618056903
   PubMed Web of Science ®Google Scholar
• StoneGWWhiteHDOhmanEMBivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy ACUITY trialLancet2007b3699071917368152
   PubMed Web of Science ®Google Scholar
• TelfordAMWilsonCTrial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndromeLancet19811122586112564
   PubMed Web of Science ®Google Scholar
• TherouxPOuimetHMcCansJAspirin, heparin, or both to treat acute unstable anginaN Engl J Med19883191105113050522
   PubMed Web of Science ®Google Scholar
• TherouxPWatersDQiuSAspirin versus heparin to prevent myocardial infarction during the acute phase of unstable anginaCirculation199388204588222097
   PubMed Web of Science ®Google Scholar
• TIMI-8Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial InfarctionAm Heart J20021432293411835024
   PubMed Web of Science ®Google Scholar
• TopolEJBonanRJewittDUse of a direct antithrombin hirulog, in place of heparin during coronary angioplastyCirculation199387162298491018
   PubMed Web of Science ®Google Scholar
• VirmaniRBurkeAPFarbAPathology of the vulnerable plaqueJ Am Coll Cardiol200647C13816631505
   PubMed Web of Science ®Google Scholar
• VirmaniRKolodgieFDBurkeAPLessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesionsArterioscler Thromb Vasc Biol20002012627510807742
   PubMed Web of Science ®Google Scholar
• VoeltzMDPatelADFeitFEffect of anemia on hemorrhagic complications and mortality following percutaneous coronary interventionAm J Cardiol2007991513717531572
   PubMedGoogle Scholar
• WaksmanRWolframRMTorgusonRLSwitching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH – a multicenter clinical trialJ Invasive Cardiol200618370516877786
   PubMedGoogle Scholar
• WeitzJILow-molecular-weight heparinsN Engl J Med1997337688989278467
   PubMed Web of Science ®Google Scholar
• WeitzJIHudobaMMasselDClot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitorsJ Clin Invest199086385912384594
   PubMed Web of Science ®Google Scholar
• WeitzJILeslieBHudobaMThrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitorsCirculation199897544529494024
   PubMed Web of Science ®Google Scholar
• WhiteHThrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trialLancet200135818556311741625
   PubMed Web of Science ®Google Scholar
• WilliamsDOKirbyMGMcPhersonKAnticoagulant treatment of unstable anginaBr J Clin Pract19864011463518780
   PubMedGoogle Scholar
• YusufSMehtaSRChrolaviciusSComparison of fondaparinux and enoxaparin in acute coronary syndromesN Engl J Med2006a35414647616537663
   PubMed Web of Science ®Google Scholar
• YusufSMehtaSRChrolaviciusSEffects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trialJAMA2006b29515193016537725
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSREffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med200134549450211519503
   PubMed Web of Science ®Google Scholar